Healthcare
Recursion Pharmaceuticals, Inc.(RXRX)
Live Price
Offline$3.15
+0.00% today
1Y Change
-34.59%
Window
Jun 20, 2025 โ Jun 15, 2026
- Market Cap
- $1.57B
- Revenue Growth
- +26.9%
- EPS Growth
- +14.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 20, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Recursion Pharmaceuticals, Inc. (RXRX) is a Healthcare stock with a market cap of $1.57B and listed on NASDAQ. The stock last traded around $3.15 and down 34.6% across the available one-year price window (Jun 20, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +26.9%, EPS growth of +14.8%, a dividend yield of 0.0%. What stands out right now is revenue +26.9%, EPS +14.8%, free cash flow -1.5% with operating margin -869.3% and ROIC -48.1%. Valuation already assumes a fairly strong business story at price/sales 21.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RXRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+26.9% vs +7.6% peer median
Operating Margin
Below sector median
-869.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 4, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +26.9% and EPS at +14.8%, with operating margin around -869.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 4, 2026 | โ | -4.3% | -7.4% | +2.6% |
2026 Feb 25, 2026 | +25.0% | +0.0% | -3.4% | -15.9% |
2025 Nov 5, 2025 | +5.3% | -6.9% | -6.2% | -0.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RXRX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RXRX Max Drawdown
-58.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RXRX and SPY.
Company Overview
Recursion Pharmaceuticals, Inc.
NASDAQ Global Select
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
- Leadership
- Najat Khan
- IPO Date
- Apr 16, 2021
- Employees
- 800
- Street Address
- 41 South Rio Grande Street
- Mailing
- Salt Lake City, UT, 84101
- Region
- Salt Lake City, UT, US
- Reporting Currency
- USD
- Investor Line
- 385 269 0203
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 21.1
- Price/Book
- 1.6
Growth
- Revenue
- +26.9%
- EPS
- +14.8%
- Free Cash Flow
- -1.5%
Profitability
- Gross Margin
- -32.1%
- Operating Margin
- -869.3%
- Net Margin
- -864.7%
- ROE
- -64.0%
- ROIC
- -48.1%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 5.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.